Factor VIII and other hemostasis variables are related to incident diabetes in adults: The atherosclerosis risk in communities (ARIC) study

Diabetes Care

Volumn 22, Issue 5, 1999, Pages 767-772

  Duncan, Bruce B ^a,b,f   Schmidt, Maria Ines ^a,b   Offenbacher, Steven ^c   Wu, Kenneth K ^d   Savage, Peter J ^e   Heiss, Gerardo ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f Department of Social Medicine ^*  (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; GLUCOSE; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

AGE; ARTICLE; BODY MASS; CASE FINDING; DIABETOGENESIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTIAL THROMBOPLASTIN TIME; RACE; RISK FACTOR; SEX DIFFERENCE; SMOKING;

EID: 0032954652     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.5.767     Document Type: Article

References (52)

1. Folsom AR, Conlan MG, Davis CE, Wu KK, for the Atherosclerosis Risk in Communities (ARIC) Investigators: Relations between hemostasis variables and cardiovascular risk factors in middle-aged adults. Ann Epidemiol 2:481-494, 1992
2. Mansfield MW, Heywood DM, Grant PJ: Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation 94: 2171-2176, 1996
3. Yudkin JS: Is insulin vasculotoxic? Diabelologia 40:5140-5146, 1997
4. Tracy RP, Bovill EG, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ: Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 15:1269-1279, 1995
5. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ: Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 88:601-607, 1994
6. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE: Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96:1102-1108, 1997
7. Stern MP: Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 44:369-374, 1995
8. Jarrett RJ, Shipley MJ: Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease: putative association via common antecedents; further evidence from the Whitehall Study. Diabetologia 31:737-740, 1988
9. Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL, Sharrett AR, Davis CE, Heiss G: Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. Metabolism 45:699-706, 1996
10. Zimmet PZ, Collins VR, Dowse GK, Alberti KG, Tuomilehto J, Knight LT, Gareeboo H, Chitson P, Fareed D: Is hyperinsulinaemia a central characteristic of a chronic cardiovascular risk factor clustering syndrome? Mixed findings in Asian Indian, Creole and Chinese Mauritians. Mauritius Noncommunicable Disease Study Group. Diabet Med 11:388-396, 1994
11. Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD: von Willebrand factor is an acute phase reactant in man. Thromb Res 53:387-394, 1989
12. Van Der Poll T, van Deventer SJ, Pasterkamp G, van Mourik JA, Buller HR, ten Cate JW: Tumor necrosis factor induces von Willebrand factor release in healthy humans. Thromb Haemost 67:623-626, 1992
13. Mathonnet F, Mazancourt PD, Denninger MH, Morot M, Benattar N, Giudicelli Y: Role of factor VIII on activated protein C resistance ratio in inflammatory diseases. Br J Haematol 95:423-425, 1996
14. Fuller GM: Fibrinogen: a multifunctional acute phase protein. In Acute Phase Proteins: Molecular Biology, Biochemistry and Clinical Applications. Mackiewicz A, Kushner I, Baumann H, Eds. Boca Raton, FL, CRC Press, 1993, p. 169-183
15. Noe DA: A mathematical model of coagulation factor VIII kinetics. Haemostasis 26:289-303, 1996
16. Blann A: von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci 50:125-134, 1993
17. Li X, Gabriel D: The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding. Biochemistry 36:10760-10767, 1997
18. ARIC Investigators: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 129:687-702, 1989
19. Doumas BT, Watson WA, Biggs HG: Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta 31:8796, 1971
20. National Heart, Lung, and Blood Institute: Atherosclerosis Risk in Communities (ARIC) Study Protocol, Manual 9: Hemostasis Determinations. Chapel Hill, NC, ARIC Study Coordinating Center, School of Public Health, University of North Carolina, 1987, p. 1-87
21. Papp AC, Hatzakis H, Bracey A, Wu KK: ARIC hemostasis study: I. Development of blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost 61:15-19, 1989
22. Clauss A: Gerinnungsphysiologische Schnell-methode zur Bestimmung des Fibrinogens. Acta Haematol 17:237-246, 1957
23. Chambless LE, McMahon RL, Wu KK, Folsom AR, Finch A, Shen Y-L: Short-term intraindividual variability in hemostasis factors: the ARIC Study. Ann Epidemiol 2:723-733, 1992
24. Stouthard JM, Levi M, Hack CE, Veenhof CH, Romijn HA, Sauerwein HP, Van Der Poll T: Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 76:738-742, 1996
25. Miletich JP: Activated partial thromboplastin time. In Hematology Basic Principles and Practice. Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, Eds. New York, Churchill Livingstone, 1995, p. L85-L86
26. Bhagat K, Moss R, Collier J, Vallance P: Endothelial "stunning" following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res 32:822-829, 1996
27. Wang P, Ba ZE, Chaudry IH: Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 266:H2535-H2541, 1994
28. Silveira A, Karpe F, Johnsson H, Bauer KA, Hamsten A: In vivo demonstration in humans that large postprandial triglyceriderich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arterioscler Thromb Biol 16:1333-1339, 1996
29. Mukherjee M, Dawson G, Sembhi K, Kakkar W: Triglyceride dependence of factor VII coagulant activity in deep venous thrombosis. Thromb Haemost 76:500-501, 1996
30. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS: Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389:610-614, 1997
31. Corbett J, Serup P, Bonner-Weir S, Nielsen JH: Beta-cell ontogeny: growth and death. Diabetologia 40:B27-B32, 1997
32. Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G, Baron AD: Obesity/ insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97:2601-2610, 1996
33. Baron AD, Clark MG: Role of blood flow in the regulation of muscle glucose uptake. Annu Rev Nutr 17:487-499, 1997
34. Utriainen T, Nuutila P, Takala T, Vicini P, Ruotsalainen U, Ronnemaa T, Tolvanen T, Raitakari M, Haaparanta M, Kirvela O, Cobelli C, Yki-Jarvinen H: Intact insulin stimulation of skeletal muscle blood flow, its heterogeneity and redistribution, but not of glucose uptake in non-insulin-dependent diabetes mellitus. J Clin Invest 100:777-785, 1997
35. Clark MG, Colquhoun EQ, Rattigan S, Dora KA, Eldershaw TPD, Hall JL, Yeh J: Vascular and endocrine control of muscle metabolism. Am J Physiol 268:E797-E812, 1995
36. Rattigan S, Clark MG, Barrett EJ: Hemodynamic actions of insulin in rat skeletal muscle: evidence for capillary recruitment. Diabetes 46:1381-1388, 1997
37. Baron AD: The coupling of glucose metabolism and perfusion in human skeletal muscle: the potential role of endothelium-derived nitric oxide. Diabetes 45 (Suppl. 1):S105-S109, 1996
38. 18Ffluorodeoxy-glucose and positron emission tomography. J Clin Invest 97:1741-1747, 1996
39. Baron AD, Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G: Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 96:786-792, 1995
40. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA: Estrogen improves endothelium-dependent, flow-mediate vasodilation in postmenopausal women. Ann Intern Med 121:936-941, 1994
41. Polderman KH, Stehouwer CD, van KG, Gooren LJ: Effects of insulin infusion on endothelium-derived vasoactive substances. Diabetologia 39:1284-1292, 1996
42. Anastasiou E, Megas J, Lekakis JP, Souvatzoglou A, Alevizaki M, Stamatelopoulos SF, Papamichael CM: Impaired endothelium-dependent vasodilatation in women with previous gestational diabetes. Diabetes Care 21:2111-2115, 1998
43. Hotamisligil GS, Spiegelman BM: Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43:1271-1278, 1994
44. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB: The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95:2111-2119, 1995
45. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T: Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83:2907-2910, 1998
46. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin J, Klein S, Coppack SW: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196-4200, 1997
47. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665-668, 1996
48. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10, 1997
49. Feingold KR, Grunfeld C: Role of cytokines in inducing hyperlipidemia. Diabetes 41 (Suppl 2):97-101, 1992
50. Bonadonna RC, Bonora E: Glucose and free fatty acid metabolism in human obesity: relationships to insulin resistance. Diabetes Rev 5:21-51, 1997
51. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD: Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100:1230-1239, 1997
52. Borch-Johnsen K, for the DECODE study group on behalf of the European Diabetes Epidemiology Study Group: Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? BMJ 317:371-375, 1998